Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance
Language English Country Canada Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22040924
DOI
10.1016/j.ijid.2011.09.011
PII: S1201-9712(11)00190-1
Knihovny.cz E-resources
- MeSH
- Antifungal Agents adverse effects therapeutic use MeSH
- Aspergillus chemistry isolation & purification MeSH
- Bronchoalveolar Lavage Fluid chemistry MeSH
- Bronchoscopy MeSH
- Adult MeSH
- Galactose analogs & derivatives MeSH
- Hematologic Neoplasms complications MeSH
- Invasive Pulmonary Aspergillosis diagnosis drug therapy microbiology MeSH
- Cohort Studies MeSH
- Hematologic Diseases complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Mannans analysis blood MeSH
- Adolescent MeSH
- Young Adult MeSH
- Neutropenia complications MeSH
- Predictive Value of Tests MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antifungal Agents MeSH
- galactomannan MeSH Browser
- Galactose MeSH
- Mannans MeSH
BACKGROUND: We evaluated the performance of a galactomannan (GM) assay in bronchoalveolar lavage (BAL) fluid compared to serum samples for the diagnosis of invasive pulmonary aspergillosis (IPA) in patients with hematological diseases. METHODS: Two hundred and fifty-five bronchoscopies were performed on 230 patients. Bronchial and alveolar samples from BAL fluid as well as serum samples were analyzed in the GM assay. RESULTS: Twenty-eight cases of IPA (11%) were diagnosed. The sensitivity, specificity, positive predictive value, and negative predictive value of the GM assay using a cut-off of 0.5 were 57.1%, 99.3%, 94.1%, and 92.5%, respectively, for the alveolar sample; 44.0%, 99.3%, 91.7%, and 91.4%, respectively, for the bronchial sample; and 60.7%, 100%, 100%, and 92.9%, respectively, for serum. The highest sensitivity (78.6%) with good specificity (98.6%) was obtained with a 'triple detection' of GM in bronchial, alveolar, and serum samples. Neutropenia and antifungal therapy for only 24h increased the sensitivity, while antifungal treatment for ≥ 2 days decreased assay performance. Moreover, a trend towards a higher volume of aspirated fluid in GM-negative BAL (p=0.092) was observed. CONCLUSIONS: In contrast to recently published data, we found only moderate sensitivity, but high specificity and high positive predictive value of the detection of GM in BAL fluid. In addition, neutropenia, antifungal therapy, and BAL standardization affected GM assay performance.
References provided by Crossref.org